Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by bluebird bio, Inc.
< Previous
1
2
Next >
bluebird bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 05, 2023
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer
January 03, 2023
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
FDA Lifts Partial Clinical Hold for bluebird bio’s Sickle Cell Disease (SCD) Studies for Patients Under the Age of 18
December 19, 2022
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio Sells Priority Review Voucher for $102 Million
November 30, 2022
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio Reports Third Quarter 2022 Financial Results and Highlights Operational Progress
November 07, 2022
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio to Present at the 31st Annual Credit Suisse Healthcare Conference
November 02, 2022
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio Receives FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy (CALD)
September 16, 2022
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
Jason Cole, Chief Strategy and Financial Officer, to Depart bluebird bio This Fall
September 12, 2022
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio Announces September Investor Events
August 29, 2022
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio Announces U.S. Commercial Infrastructure to Enable Patient Access to ZYNTEGLO®, the First and Only FDA-Approved Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions
August 17, 2022
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio Announces FDA Approval of ZYNTEGLO®, the First Gene Therapy for People with Beta-Thalassemia Who Require Regular Red Blood Cell Transfusions
August 17, 2022
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio Reports Second Quarter 2022 Financial Results and Highlights Operational Progress
August 04, 2022
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
FDA Advisory Committee Unanimously Supports beti-cel Gene Therapy for People with beta-thalassemia Who Require Regular Red Blood Cell Transfusions
June 10, 2022
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
FDA Advisory Committee Unanimously Endorses eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy
June 09, 2022
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio stock trading halted today June 9th and tomorrow June 10th
June 09, 2022
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio Announces Posting of Briefing Documents for Upcoming FDA Advisory Committee Meeting
June 07, 2022
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio Reports First Quarter 2022 Financial Results and Highlights Operational Progress
May 09, 2022
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio Initiates Restructuring to Reduce Operating Expenses and Advance Near-term Opportunities to Bring Potentially Curative Gene Therapies to Patients in the US
April 05, 2022
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD)
January 18, 2022
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio to Provide Update on Program Milestones and 2022 Financial Outlook at the 40th Annual J.P. Morgan Healthcare Conference
January 11, 2022
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 05, 2022
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio Announces Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Clinical Program
December 20, 2021
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio Announces FDA Priority Review of Biologics License Application for eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) in Patients Without a Matched Sibling Donor
December 17, 2021
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
New and Updated Data Demonstrating Sustained Treatment Response in Patients Treated in Largest Sickle Cell Gene Therapy Program To-Date Presented at ASH21 and Published in NEJM
December 12, 2021
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
New Data at ASH21, Published in NEJM Further Demonstrate beti-cel as a Potentially Curative One-Time Gene Therapy for β-thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable TI and Normal or Near-Normal Adult Hb Levels
December 11, 2021
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio Announces FDA Priority Review of Biologics License Application for beti-cel Gene Therapy for Patients with β-thalassemia Who Require Regular Red Blood Cell Transfusions
November 22, 2021
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio Reports Third Quarter Financial Results and Recent Operational Progress
November 05, 2021
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio and Federal Realty to Establish Biotech Footprint at Assembly Row
November 05, 2021
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio Completes Planned Business Separation
November 04, 2021
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
bluebird bio Sets Record Date and Distribution Date for Planned Business Separation
October 18, 2021
From
bluebird bio, Inc.
Via
Business Wire
Tickers
BLUE
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.